Driving Synthetic Biology Forward Through Adoption of Technology Enabling Rapid DNA and mRNA Synthesis

Breakthroughs in synthetic biology could help accelerate advances in applications from novel infectious disease vaccines, precision immunotherapy for cancer and antibody therapeutics to creation of engineered meat substitutes and sustainable cellular agricultural products. The post Driving Synthetic Biology Forward Through Adoption of Technology Enabling Rapid DNA and mRNA Synthesis appeared first on MedCity News.

Read More

The Overlooked Pillar of Clinical Care: Physical Therapists

Despite their measurable clinical outcomes and contributions to patient well-being, they often face a dismissive perception as mere providers of ice bags and stretch bands. However, an economic crisis is threatening this vital profession, and the blame extends beyond insurance payors. The post The Overlooked Pillar of Clinical Care: Physical Therapists appeared first on MedCity…

Read More

Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt for Hot Inflammation Target

Gilead Sciences is acquiring LEO Pharma’s oral small molecule inhibitors of STAT6, a protein key to two validated inflammation pathways. Other STAT6 drug developers include Kymera Therapeutics and Sanofi-partnered Recludix Pharma, which is presenting this week during the J.P. Morgan Healthcare Conference. The post Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt…

Read More